Last reviewed · How we verify

MenHibrix (Hib-MenCY-TT)

GlaxoSmithKline · Phase 3 active Biologic

MenHibrix (Hib-MenCY-TT) is a Conjugate vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of invasive disease caused by Haemophilus influenzae type b (Hib), Prevention of invasive disease caused by Neisseria meningitidis serogroups C and Y. Also known as: GSK biologicals' Hib-MenCY-TT.

MenHibrix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) and Neisseria meningitidis serogroups C and Y.

MenHibrix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) and Neisseria meningitidis serogroups C and Y. Used for Prevention of invasive disease caused by Haemophilus influenzae type b (Hib), Prevention of invasive disease caused by Neisseria meningitidis serogroups C and Y.

At a glance

Generic nameMenHibrix (Hib-MenCY-TT)
Also known asGSK biologicals' Hib-MenCY-TT
SponsorGlaxoSmithKline
Drug classConjugate vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The vaccine contains polysaccharide antigens from Hib and meningococcal serogroups C and Y conjugated to tetanus toxoid (TT) as a carrier protein. This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in robust antibody production and immunological memory against these bacterial pathogens. The vaccine is designed to provide protection against invasive bacterial infections caused by these organisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about MenHibrix (Hib-MenCY-TT)

What is MenHibrix (Hib-MenCY-TT)?

MenHibrix (Hib-MenCY-TT) is a Conjugate vaccine drug developed by GlaxoSmithKline, indicated for Prevention of invasive disease caused by Haemophilus influenzae type b (Hib), Prevention of invasive disease caused by Neisseria meningitidis serogroups C and Y.

How does MenHibrix (Hib-MenCY-TT) work?

MenHibrix is a conjugate vaccine that stimulates the immune system to produce antibodies against Haemophilus influenzae type b (Hib) and Neisseria meningitidis serogroups C and Y.

What is MenHibrix (Hib-MenCY-TT) used for?

MenHibrix (Hib-MenCY-TT) is indicated for Prevention of invasive disease caused by Haemophilus influenzae type b (Hib), Prevention of invasive disease caused by Neisseria meningitidis serogroups C and Y.

Who makes MenHibrix (Hib-MenCY-TT)?

MenHibrix (Hib-MenCY-TT) is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is MenHibrix (Hib-MenCY-TT) also known as anything else?

MenHibrix (Hib-MenCY-TT) is also known as GSK biologicals' Hib-MenCY-TT.

What drug class is MenHibrix (Hib-MenCY-TT) in?

MenHibrix (Hib-MenCY-TT) belongs to the Conjugate vaccine class. See all Conjugate vaccine drugs at /class/conjugate-vaccine.

What development phase is MenHibrix (Hib-MenCY-TT) in?

MenHibrix (Hib-MenCY-TT) is in Phase 3.

What are the side effects of MenHibrix (Hib-MenCY-TT)?

Common side effects of MenHibrix (Hib-MenCY-TT) include Injection site pain/erythema, Fever, Irritability, Drowsiness.

Related